EUVIMEDEUVIMED entdecken
Crossref

Proteomics analysis reveal early event molecular effectors of anti-CD19 CAR-T cell therapy in hematological cancer

John Oluwafemi Teibo, Roberta Maraninchi Silveira, Virginia Campos Silvestrini, Izadora Archiolli, Ana Paula Masson, Beatriz Pereira de Morais, Dayane Schmidt, Matheus Henrique Dos Santos, Germano Aguiar Ferreira, Carolina Hassibe Thomé, Dominic Helm, Raja Sekhar Nirujogi und 4 weitere

Journal of Proteomics · 2025

DOI: 10.1016/j.jprot.2025.105507 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Proteomics, 2025. Verfasst von John Oluwafemi Teibo und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Immunology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo 14049-900, Brazil; Cente…. Hauptthemen laut MEDLINE: Proteomics, Immunotherapy, Adoptive, Antigens, CD19, Hematologic Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Conselho Nacional de Desenvolvimento Científico e Tecnológico, International Union of Biochemistry and Molecular Biology, Biochemical Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor T-cell (CAR-T) therapy is at the forefront of the field of cell immunotherapy. In this study, we generated an anti-CD19 CAR-Jurkat T cell line using a locally produced second-generation anti-CD19 CAR construct, which allowed us to analyse early proteomic changes that are crucial for comprehending the signalling pathways and mechanism of action of this CAR-T cell. SILAC-heavy tagged Raji B-cells and anti-CD19 CAR-Jurkat T-cells were co-cultured for ten minutes. The proteomic profiles were acquired via DIA methodology on the Orbitrap Astral LC-MS/MS platform. The proteome was extensively covered, resulting in about 8800 protein identifications at 1 % FDR. The effector CAR-Jurkat cells showed proteomic changes involving antigen presentation by CD74. The target Raji B-cells exhibited more significant alterations. Effector proteins, namely CD247, CD28, DAP, LCK, p38 MAPK, and CASP3, were validated, as they have critical roles in antigen presentation, T-cell activation, and apoptosis. Pharmacological inhibition of LCK using Dasatinib further suggested its pivotal role in early CAR-T signalling. This study led us to identify proteins that function as molecular effectors of anti-CD19 CAR-T cell therapy during the initial phases of CAR-T-target cell engagement, advancing our knowledge of the mechanism and signalling pathways that will support CAR-T cell development. SIGNIFICANCE: Chimeric antigen receptor T-cell (CAR-T cell) therapy is state-of-the-art in cell and immunotherapy. Determining important players in cellular communication and signalling mediated by membranes and intracellular proteins requires understanding the connection between tumours and modified cells. We employed global proteomics in this study to better grasp the functional protein networks using a high-sensitivity mass spectrometric platform for protein identification and quantification. We identified proteins as molecular effectors of anti-CD19 CAR-T cell treatment during the early stages of CAR-T-target cell interaction. Our understanding of the mechanism and signalling pathways will promote the development of new CAR constructs and improve the efficacy and ability to overcome the resistance of this innovative cancer treatment strategy, which will advance the identification of adjuvant molecules for the regulation of CAR-T responses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProteomicsImmunotherapy, AdoptiveAntigens, CD19Hematologic NeoplasmsReceptors, Chimeric AntigenT-LymphocytesProteomeNeoplasm ProteinsHumansJurkat CellsCell Line, Tumor

Stichwörter der Autor:innen

CAR-T cellEarly Signalling eventHematological CancerMolecular effectorsProteomicsSILAC

Substanzen

Antigens, CD19Receptors, Chimeric AntigenProteomeNeoplasm ProteinsCD19 molecule, human

Autor:innen und Institutionen

  • Department of Biochemistry and Immunology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo 14049-900, Brazil; Center for Cell-based Therapy CTC, Regional Blood Center of Ribeirão Preto,…
  • Center for Cell-based Therapy CTC, Regional Blood Center of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo 14051-140, Brazil.
  • Department of Biochemistry and Immunology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo 14049-900, Brazil. Electronic address: masson@usp.br.
  • Center for Cell-based Therapy CTC, Regional Blood Center of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo 14051-140, Brazil. Electronic address: Dayaneschmidt@usp.br.
  • Center for Cell-based Therapy CTC, Regional Blood Center of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo 14051-140, Brazil. Electronic address: matheus.henrique.santos@usp.br.
  • Center for Cell-based Therapy CTC, Regional Blood Center of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo 14051-140, Brazil. Electronic address: carolhthome@hemocentro.fmrp.usp.br.

Förderung

  • Conselho Nacional de Desenvolvimento Científico e Tecnológico
  • International Union of Biochemistry and Molecular Biology
  • Biochemical Society
  • Royal Society of Chemistry
  • State of Sao Paulo Research Foundation
  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
  • European Association For Cancer Research

Zitieren

APA

Teibo, J. O., Silveira, R. M., Silvestrini, V. C., Archiolli, I., Masson, A. P., de Morais, B. P., Schmidt, D., Dos Santos, M. H., Ferreira, G. A., Thomé, C. H., Helm, D., Nirujogi, R. S., Alessi, D. R., Picanço-Castro, V., de Souza, L. E. B., & Faça, V. M. (2025). Proteomics analysis reveal early event molecular effectors of anti-CD19 CAR-T cell therapy in hematological cancer. Journal of Proteomics. https://doi.org/10.1016/j.jprot.2025.105507

Vancouver

Teibo JO, Silveira RM, Silvestrini VC, Archiolli I, Masson AP, de Morais BP, et al. Proteomics analysis reveal early event molecular effectors of anti-CD19 CAR-T cell therapy in hematological cancer. Journal of Proteomics. 2025. doi:10.1016/j.jprot.2025.105507

BibTeX
@article{Teibo2025,
  author = {Teibo, John Oluwafemi and Silveira, Roberta Maraninchi and Silvestrini, Virginia Campos and Archiolli, Izadora and Masson, Ana Paula and de Morais, Beatriz Pereira and Schmidt, Dayane and Dos Santos, Matheus Henrique and Ferreira, Germano Aguiar and Thomé, Carolina Hassibe and Helm, Dominic and Nirujogi, Raja Sekhar and Alessi, Dairo Renato and Picanço-Castro, Virginia and de Souza, Lucas Eduardo Botelho and Faça, Vitor Marcel},
  title = {Proteomics analysis reveal early event molecular effectors of anti-CD19 CAR-T cell therapy in hematological cancer},
  journal = {Journal of Proteomics},
  year = {2025},
  doi = {10.1016/j.jprot.2025.105507}
}
Kostenlos starten →